Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Public ClinicalTrials.gov record NCT02168946. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Study identification
- NCT ID
- NCT02168946
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
- Industry
- Enrollment
- 77 participants
Conditions and interventions
Conditions
Interventions
- Best Available Therapy Drug
- Vabomere Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2014
- Primary completion
- Jul 20, 2017
- Completion
- Jul 20, 2017
- Last update posted
- Mar 3, 2019
2014 – 2017
United States locations
- U.S. sites
- 20
- U.S. states
- 12
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Hartford | Connecticut | 06102 | — |
| Not listed | Tampa | Florida | 33606 | — |
| Not listed | Augusta | Georgia | 30912 | — |
| Not listed | Chicago | Illinois | 60611 | — |
| Not listed | Chicago | Illinois | 60612 | — |
| Not listed | Evanston | Illinois | 60201 | — |
| Not listed | Indianapolis | Indiana | 46202 | — |
| Not listed | Detroit | Michigan | 48201 | — |
| Not listed | Royal Oak | Michigan | 48073 | — |
| Not listed | New Brunswick | New Jersey | 08901 | — |
| Not listed | Buffalo | New York | 14215 | — |
| Not listed | Flushing | New York | 11355 | — |
| Not listed | New York | New York | 10032 | — |
| Not listed | The Bronx | New York | 10467 | — |
| Not listed | Charlotte | North Carolina | 28207 | — |
| Not listed | Durham | North Carolina | 27710 | — |
| Not listed | Cleveland | Ohio | 44106 | — |
| Not listed | Philadelphia | Pennsylvania | 19104 | — |
| Not listed | Pittsburgh | Pennsylvania | 15213 | — |
| Not listed | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02168946, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 3, 2019 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02168946 live on ClinicalTrials.gov.